Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

Left ventricular assist devices (LVADs) are increasingly common across the heart failure population. Right ventricular failure (RVF) is a feared complication that can occur in the early post-operative ...

wakehealth.edu Objective To determine if there is a significant difference in the predictive abilities of left ventricular hypertrophy (LVH) detected by ECG-LVH versus LVH ascertained by cardiac ...

Endothelial dysfunction in the coronary arteries can lead to acute coronary events. Left ventricular dysfunction will cause the progression of heart failure, and left ventricular fibrosis and ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

A national clinical trial is underway to compare a novel mechanical heart pump to the only device currently used to treat end-stage heart failure. The INNOVATE study, led by University of Michigan, wi ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Chronic: You have a history of heart failure, but your condition is relatively stable with no symptoms or with manageable symptoms. Left-sided heart failure involves the left ventricle (bottom left ...

Participants 4989 adults (mean age 36 years, 52% women) free of clinical heart failure at baseline. Outcome measures Incident heart failure, echocardiographic measures of left ventricular systolic ...